A Study Of The Selective PKC-β Inhibitor MS- 553
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Acalabrutinib
Related studies linked through entity extraction aliases.
A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
A Phase 1 Study of Acalabrutinib in Japanese Adult Patients With Advanced B-cell Malignancies
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- Status
- RECRUITING
- Phase
- PHASE2
A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
- Status
- WITHDRAWN
- Phase
- PHASE3
Acalabrutinib (ACP-196) Alone and in Combination With Pembrolizumab in Ovarian Cancer (KEYNOTE191)
- Status
- COMPLETED
- Phase
- PHASE2
Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Study of the Combination of Acalabrutinib (ACP-196) and Pembrolizumab in Advanced Head and Neck Squamous Cell Carcinoma
- Status
- COMPLETED
- Phase
- PHASE2
Pembrolizumab Alone and In Combination With Acalabrutinib (ACP-196) in Subjects With Advanced Non-small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE2
ACP-196 Versus Placebo in Subjects With Rheumatoid Arthritis on Background Methotrexate
- Status
- COMPLETED
- Phase
- PHASE2
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL
- Status
- COMPLETED
- Phase
- PHASE1
An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1